Sullivan Christopher Ryan
SEC insider (Form 3/4/5 filer). CIK 0001810417. Chief Financial Officer at Avalo Therapeutics, Inc. (AVTX). 31 reported Form 4/5 transactions since Sep 2024; latest on Sep 16, 2026. Located in WAYNE, PA.
Companies Sullivan Christopher Ryan has filed insider reports for
- Avalo Therapeutics, Inc. (AVTX): Officer, Chief Financial Officer
Sullivan Christopher Ryan
CIK: 0001810417
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
Avalo Therapeutics, Inc.
Discretionary Trading P&L
Holdings
Transaction History (31 total)
- Sep 16, 2026AVTX
Avalo Therapeutics, Inc.
SaleDirect12.4K shares at avg. $16.33$202K - Sep 16, 2026AVTX
Avalo Therapeutics, Inc.
ExerciseDirect12.4K shares at avg. $9.88$122K - Sep 10, 2026AVTX
Avalo Therapeutics, Inc.
SaleDirect10.2K shares at avg. $17.62$179K - Sep 10, 2026AVTX
Avalo Therapeutics, Inc.
ExerciseDirect10.2K shares at avg. $8.04$82K - Aug 18, 2026AVTX
Avalo Therapeutics, Inc.
ExerciseDirect31K shares at avg. $9.88$307K - Aug 18, 2026AVTX
Avalo Therapeutics, Inc.
SaleDirect31K shares at avg. $20.05$622K - Aug 17, 2026AVTX
Avalo Therapeutics, Inc.
SaleDirect3.7K shares at avg. $19.94$75K - Aug 17, 2026AVTX
Avalo Therapeutics, Inc.
ExerciseDirect37.9K shares at avg. $9.88$375K - Aug 17, 2026AVTX
Avalo Therapeutics, Inc.
ExerciseDirect2.9K shares at avg. $9.88$28K - Aug 17, 2026AVTX
Avalo Therapeutics, Inc.
SaleDirect37.9K shares at avg. $19.85$753K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Sep 16, 2026 | AVTX Avalo Therapeutics, Inc. | Sale | 12,394 | $16.33 | $202,437 | Direct |
| Sep 16, 2026 | AVTX Avalo Therapeutics, Inc. | Exercise | 12,394 | $9.88 | $122,453 | Direct |
| Sep 10, 2026 | AVTX Avalo Therapeutics, Inc. | Sale | 10,185 | $17.62 | $179,457 | Direct |
| Sep 10, 2026 | AVTX Avalo Therapeutics, Inc. | Exercise | 10,185 | $8.04 | $81,887 | Direct |
| Aug 18, 2026 | AVTX Avalo Therapeutics, Inc. | Exercise | 31,031 | $9.88 | $306,586 | Direct |
| Aug 18, 2026 | AVTX Avalo Therapeutics, Inc. | Sale | 31,031 | $20.05 | $622,324 | Direct |
| Aug 17, 2026 | AVTX Avalo Therapeutics, Inc. | Sale | 3,749 | $19.94 | $74,762 | Direct |
| Aug 17, 2026 | AVTX Avalo Therapeutics, Inc. | Exercise | 37,945 | $9.88 | $374,897 | Direct |
| Aug 17, 2026 | AVTX Avalo Therapeutics, Inc. | Exercise | 2,876 | $9.88 | $28,415 | Direct |
| Aug 17, 2026 | AVTX Avalo Therapeutics, Inc. | Sale | 37,945 | $19.85 | $753,333 | Direct |
1-10 of 31 transactions